UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
|
||||
Washington, D.C. 20549
|
||||
FORM 8-K
|
||||
CURRENT REPORT
|
||||
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
|
||||
November 13, 2012
Date of Report (Date of earliest event reported)
|
||||
HESKA CORPORATION
(Exact name of Registrant as specified in its charter)
|
||||
Delaware
|
000-22427
|
77-0192527
|
||
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
||
3760 Rocky Mountain Avenue
Loveland, Colorado 80538
(Address of principal executive offices, including zip code)
|
||||
(970) 493-7272
(Registrant’s telephone number, including area code)
|
||||
Not Applicable
(Former name or former address, if changed since last report)
|
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
|
||||
[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
||||
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
||||
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
||||
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
||||
|
HESKA CORPORATION
a Delaware corporation
|
|
|
|
Dated: November 13, 2012
|
By: /s/ Jason A. Napolitano
Jason A. Napolitano
Executive Vice President, Chief Financial Officer
and Secretary
|
Exhibit Number
|
Description
|
99.1
|
Press Release dated November 13, 2012
|
At Heska Corporation:
|
At Hayden IR:
|
Jason Napolitano, Executive Vice President & CFO
|
Brett Maas, Managing Partner
|
(970) 493-7272, Ext. 4105
|
(646) 536-7331
|
brett@haydenir.com
|
•
|
Consolidated revenue was $16.9 million, a decrease of 4% as compared to the $17.6 million in the third quarter of 2011.
|
•
|
Core Companion Animal Health revenue of $13.5 million, decreased 5% as compared to $14.3 million for the third quarter of 2011.
|
•
|
Other Vaccines, Pharmaceuticals and Products (OVP) revenues were up 1% to $3.4 million from $3.3 million in the third quarter of 2011.
|
•
|
Gross profit was $6.7 million, or a 39.8% gross margin, as compared to gross profit of $6.8 million, or a 38.8% gross margin, for the third quarter of 2011.
|
•
|
Operating loss was $27 thousand as compared to $408 thousand operating income in the third quarter of 2011.
|
•
|
Heska completed the quarter with $5.7 million in cash, no debt and $18.1 million in working capital.
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
2011 | 2012 |
2011
|
2012
|
|||||||||||||
Revenue, net:
|
||||||||||||||||
Core companion animal health
|
$ | 14,263 | $ | 13,530 |
$
|
44,727 |
$
|
45,811 | ||||||||
Other vaccines, pharmaceuticals and products
|
3,345 | 3,376 | 9,833 | 8,541 | ||||||||||||
Total revenue, net
|
17,608 | 16,906 | 54,560 | 54,352 | ||||||||||||
Cost of revenue
|
10,781 | 10,180 | 31,966 | 30,655 | ||||||||||||
Gross profit
|
6,827 | 6,726 | 22,594 | 23,697 | ||||||||||||
Operating expenses:
|
||||||||||||||||
Selling and marketing
|
3,753
|
4,381 | 11,283 | 14,020 | ||||||||||||
Research and development
|
311 | 180 | 1,345 | 717 | ||||||||||||
General and administrative
|
2,355
|
2,192 | 7,131 | 7,522 | ||||||||||||
Total operating expenses
|
6,419
|
6,753 | 19,759 | 22,259 | ||||||||||||
Operating income (loss)
|
408
|
|
(27 | ) | 2,835 |
|
1,438 | |||||||||
Interest and other (income) expense, net
|
(64
|
) | (16 | ) | 101 | 69 | ||||||||||
Income (loss) before income taxes
|
472
|
|
(11 | ) | 2,734 |
|
1,369 | |||||||||
Income tax expense:
|
|
|
||||||||||||||
Current tax expense | 30 | 16 | 189 | 98 | ||||||||||||
Deferred tax expense | 154 | 5 | 884 | 457 | ||||||||||||
Total income tax expense | 184 | 21 | 1,073 | 555 | ||||||||||||
Net income (loss)
|
$
|
288
|
|
$
|
(32
|
) |
$
|
1,661 |
|
$
|
814 | |||||
Basic net income (loss) per share
|
$ | 0.06 |
|
$ | (0.01 | ) |
$
|
0.32
|
|
$
|
0.15 | |||||
Diluted net income (loss) per share
|
$ | 0.05 |
|
$ | (0.01 | ) |
$
|
0.31 |
|
$
|
0.15 | |||||
Shares used for basic net income (loss) per share
|
5,239 | 5,350 | 5,235 | 5,314 | ||||||||||||
Shares used for diluted net income (loss) per share
|
5,411 | 5,350 | 5,337 | 5,503 |
December 31,
2011
|
September 30,
2012
|
||||||
Cash and cash equivalents
|
$
|
6,332
|
$
|
5,717 | |||
Total current assets
|
28,891
|
28,980 | |||||
Property and equipment, net | 4,869 | 5,484 | |||||
Total assets
|
61,894
|
62,978 | |||||
Dividends payable
|
--
|
536 | |||||
Total current liabilities
|
9,289
|
10,909 | |||||
Stockholders' equity
|
48,439
|
48,371 |